Relative increase of memory B-cell subsets under s.c. B-cell-depleting therapies in multiple sclerosis
By
Adriana Krenz
Anna-Lena Krickl
Felix Burner
David Freudenstein
Constantin Träger
Timo Wirth
Luisa Klotz
Klemens Angstwurm
De-Hyung Lee
Ralf A. Linker
Stefanie Haase
June 15, 2026
Clinical Scorecard: Increased Proportions of Memory B-Cell Subsets Observed in Multiple Sclerosis Patients Undergoing Subcutaneous B-Cell Depletion Therapies
At a Glance
Category Detail
Condition Key Mechanisms B-cell depletion via anti-CD20 monoclonal antibodies, with noted differences in immunomodulatory effects. Target Population Care Setting
Key Highlights
Both i.v. and s.c. anti-CD20 therapies deplete CD19+ B cells and CD20+ T cells, with varying clinical outcomes. Higher percentages of memory B cells observed in s.c. Ocre and Ofa compared to i.v. Ocre, indicating potential differences in efficacy. Memory B cell percentages increased over time in pwMS switching from i.v. Ocre to s.c. Ofa, suggesting a need for monitoring post-switch. Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Evaluate immune cell composition, serum IgG levels, and monitor for potential adverse effects related to therapy switch. Risks
Patient & Prescribing Data
Ocre can be administered i.v. every 6 months (600 mg) or s.c. twice a year (920 mg); Ofa is self-administered s.c. monthly (20 mg).
Clinical Best Practices
Standardized protocols to minimize information bias in patient recruitment. Informed consent obtained from all patients. Long-term follow-up is essential to assess the durability of treatment effects. Related Resources & Content
